The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07710885 |
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer |
RECRUITING | PHASE3 |
| NCT07673861 |
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients |
RECRUITING | NA |
| NCT07668024 |
Study of Occupational Risk Factors for Biliary and Pancreatic Cancers |
NOT_YET_RECRUITING | |
| NCT07641036 |
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07636798 |
Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07606599 |
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure |
RECRUITING | PHASE3 |
| NCT07582315 |
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) |
RECRUITING | PHASE3 |
| NCT07221253 |
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) |
RECRUITING | PHASE3 |
| NCT07021066 |
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06921928 |
Study for AZD4360 in Participants With Advanced Solid Tumours |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
